ICCM IceCure Medical Ltd. - Ordinary Shares
ICCM Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ICCM Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
ICCM Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 2 22.2%
- Buy 6 66.7%
- Hold 1 11.1%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
3 analysts · 2026-08-18Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-3.11 | $-1.53 | -1.6% |
| March 31, 2026 | $-1.80 | $-1.43 | -0.37% |
| Dec. 31, 2025 | $-2.10 | $-1.38 | -0.72% |
| Sept. 30, 2025 | $-1.80 | $-1.53 | -0.27% |
| June 30, 2025 | $-1.80 | $-1.99 | 0.19% |
| March 31, 2025 | $-0.06 | $-0.08 | 0.02% |
| Dec. 31, 2024 | $-0.08 | $-0.08 | -0.00% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ICCM | — | — | — | — | — | — |
| LFWD | $879.6K | -0.0 | -14.1% | -90.4% | -169.3% | 38.2% |
| MBAI | — | — | — | — | — | — |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F)
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 5 (0 vs prior Q) | 6 (+3 vs prior Q) | 4 (+2 vs prior Q) | 0 (-2 vs prior Q) | +2.7M |
Compared to Q4 2025. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
Company insiders 5 insiders · 0 officers · 0 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Meir Peleg | — | Aug. 14, 2026 A | 194,816 | 0 | 0 | $0 |
| Merav Nir Dotan | — | Aug. 14, 2026 A | 76,168 | 0 | 0 | $0 |
| Shay Levav | — | Aug. 14, 2026 A | 146,303 | 0 | 0 | $0 |
| Shad Good | — | Aug. 14, 2026 A | 136,698 | 0 | 0 | $0 |
| Tlalit Bussi Tel-Tzure | — | Aug. 14, 2026 A | 106,518 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Mr. Li Haixiang, Epoch Partner Investments Limited | March 27, 2026 | 45.80% | Amendment | — | SEC |
| Epoch Partner Investments Limited, Mr. Li Haixiang | May 14, 2025 | 45.70% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.